Cellectis S.A.
CLLS
$2.85
-$0.01-0.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 107.48% | 135.31% | 4,393.29% | 10,351.61% | 4,428.65% |
| Total Other Revenue | 1.80% | -30.30% | 43.47% | 24.31% | -20.84% |
| Total Revenue | 91.44% | 85.10% | 662.06% | 997.99% | 374.96% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 91.44% | 85.10% | 1,110.30% | 997.99% | 374.96% |
| SG&A Expenses | 30.81% | -7.88% | 5.59% | 60.12% | -1.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 44.90% | -1,117.14% | -93.32% | -1,558.33% | -29.92% |
| Total Operating Expenses | 3.99% | -4.33% | -16.81% | 29.16% | 4.26% |
| Operating Income | 44.30% | 32.14% | 63.27% | 47.90% | 27.14% |
| Income Before Tax | 6.78% | -436.89% | 115.40% | -33.03% | 13.59% |
| Income Tax Expenses | -- | -- | 8,466.67% | -155.66% | -174.81% |
| Earnings from Continuing Operations | 6.07% | -421.25% | 114.17% | -31.88% | 14.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.07% | -421.25% | 114.17% | -31.88% | -115.85% |
| EBIT | 44.30% | 32.14% | 63.27% | 47.90% | 27.14% |
| EBITDA | 55.36% | 39.30% | 71.79% | 55.99% | 31.64% |
| EPS Basic | 14.29% | -330.28% | 109.24% | 26.77% | -32.95% |
| Normalized Basic EPS | 14.92% | -341.67% | 110.53% | 51.82% | 27.33% |
| EPS Diluted | 14.29% | -20.67% | 108.85% | 26.77% | -32.95% |
| Normalized Diluted EPS | 14.92% | -446.93% | 110.53% | 51.82% | 27.33% |
| Average Basic Shares Outstanding | 9.58% | 39.47% | 53.44% | 80.08% | 62.37% |
| Average Diluted Shares Outstanding | 9.58% | -2.85% | 53.44% | 80.08% | 62.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |